TWI911137B - 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies) - Google Patents

用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies)

Info

Publication number
TWI911137B
TWI911137B TW107139266A TW107139266A TWI911137B TW I911137 B TWI911137 B TW I911137B TW 107139266 A TW107139266 A TW 107139266A TW 107139266 A TW107139266 A TW 107139266A TW I911137 B TWI911137 B TW I911137B
Authority
TW
Taiwan
Prior art keywords
glp
patient
surgery
peptide
bowel syndrome
Prior art date
Application number
TW107139266A
Other languages
English (en)
Chinese (zh)
Other versions
TW201922279A (zh
Inventor
科拉克 潘
安琪拉 諾頓
羅格 貝蒂娜 史塔克
克萊門 奧利佛
Original Assignee
日商武田藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商武田藥品工業股份有限公司 filed Critical 日商武田藥品工業股份有限公司
Publication of TW201922279A publication Critical patent/TW201922279A/zh
Application granted granted Critical
Publication of TWI911137B publication Critical patent/TWI911137B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107139266A 2017-11-06 2018-11-06 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies) TWI911137B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06

Publications (2)

Publication Number Publication Date
TW201922279A TW201922279A (zh) 2019-06-16
TWI911137B true TWI911137B (zh) 2026-01-11

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107139266A TWI911137B (zh) 2017-11-06 2018-11-06 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies)

Country Status (14)

Country Link
US (1) US11660328B2 (https=)
EP (1) EP3706774A4 (https=)
JP (2) JP7296958B2 (https=)
KR (1) KR102825098B1 (https=)
CN (1) CN111629745A (https=)
AR (1) AR113835A1 (https=)
AU (1) AU2018360744A1 (https=)
BR (1) BR112020008936A2 (https=)
CA (1) CA3079523A1 (https=)
IL (1) IL274098B2 (https=)
MX (1) MX2020004620A (https=)
TW (1) TWI911137B (https=)
WO (1) WO2019090209A1 (https=)
ZA (1) ZA202002080B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003736A2 (pt) * 2017-08-22 2020-09-08 Shire-Nps Pharmaceuticals, Inc. polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US20230129788A1 (en) * 2020-03-30 2023-04-27 Zealand Pharma A/S Glp-1/glp-2 dual agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
EA200801174A1 (ru) * 2005-10-24 2009-02-27 Сентокор, Инк. Антитела-миметики glp-2, полипептиды, композиции, способы и применения
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP2008247789A (ja) 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
JP6206972B2 (ja) 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
EP3082847A1 (en) * 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity

Also Published As

Publication number Publication date
RU2020118172A (ru) 2021-12-08
JP7296958B2 (ja) 2023-06-23
JP7752152B2 (ja) 2025-10-09
AU2018360744A1 (en) 2020-05-07
CN111629745A (zh) 2020-09-04
MX2020004620A (es) 2020-10-12
IL274098A (en) 2020-06-30
IL274098B1 (en) 2024-08-01
EP3706774A4 (en) 2021-09-08
EP3706774A1 (en) 2020-09-16
BR112020008936A2 (pt) 2020-10-20
AR113835A1 (es) 2020-06-17
ZA202002080B (en) 2025-11-26
CA3079523A1 (en) 2019-05-09
US11660328B2 (en) 2023-05-30
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
IL274098B2 (en) 2024-12-01
KR20200085763A (ko) 2020-07-15
TW201922279A (zh) 2019-06-16
JP2023107883A (ja) 2023-08-03
US20210169986A1 (en) 2021-06-10
KR102825098B1 (ko) 2025-06-26

Similar Documents

Publication Publication Date Title
TWI911137B (zh) 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies)
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
TW201625303A (zh) 長效ｇｌｐ－１／高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
TW201410704A (zh) 長效胰島素及胰促泌素肽之液體製劑
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
EA039082B1 (ru) Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
CN104144697A (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
JP5197012B2 (ja) 大腸連続性を伴う短腸症候群患者の治療
CN110536692A (zh) 用于治疗糖尿病的含有atpif1的药物组合物
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
CN109328069B (zh) Il-22在治疗坏死性小肠结肠炎中的用途
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
AU2016371021B2 (en) Ameliorating systemic sclerosis with death receptor agonists
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists